NDA 204760 · Averitas
Movantik
Naloxegol Oxalate · Oral
NovelLast checked: Nov 20, 2026Latest source record: Apr 13, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2014
Sep 16, 2014
Approved uses
1
Original approval plus efficacy supplements
Registered trials
2
0 Phase 3, 0 recruiting
FAERS reports
3,970
1,878 serious, 288 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 1, 2026.
MOVANTIK ® is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. MOVANTIK is an opioid antagonist indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. (1)
Mechanism: Naloxegol is an antagonist of opioid binding at the mu-opioid receptor. When administered at the recommended dose levels, naloxegol functions as a peripherally-acting mu-opioid receptor antagonist in tissues, such as the gastrointestinal tract, thereby decreasing the constipating effects of opioids. Naloxegol is a PEGylated derivative of naloxone and is a substrate for the P-glycoprotein transporter (P-gp). Also, the presence of the PEG moiety in naloxegol reduces its passive permeability as compared with naloxone. Due to the reduced permeability and increased efflux of naloxegol across the...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 16, 2014 Original approval · Type 1 - New Molecular Entity NovelReviewSummary ReviewLetter
2 products under this application
- MOVANTIK · NALOXEGOL OXALATE EQ 25MG BASE · TABLET, ORAL · Prescription
- MOVANTIK · NALOXEGOL OXALATE EQ 12.5MG BASE · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Naloxegol Oxalate" as an intervention, any sponsor and status, largest first.
AstraZenecaAstraZeneca (AZN)
NCT01623609 · 42 participants · Start Jul 2012 · Primary completion Sep 2012
Drug: Naloxegol; Naloxegol · For: Opioid Induced Constipation
Sites: London, United Kingdom
Institut Paoli-CalmettesAcademic, hospital or other
NCT04219046 · 0 participants · Start Jan 2032 · Primary completion Jan 2032
Drug: Naloxégol oxalate; Placebo oral tablet · For: Bladder Cancer; Cystostomy; Complications
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- diarrhoea386
- constipation384
- drug ineffective377
- pain367
- nausea332
- off label use275
- abdominal pain264
- abdominal pain upper229
- intentional product misuse224
- vomiting210
- death188
- fatigue187
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2010 | 2 |
| 2011 | 2 |
| 2012 | 1 |
| 2013 | 4 |
| 2014 | 2 |
| 2015 | 371 |
| 2016 | 675 |
| 2017 | 575 |
| 2018 | 352 |
| 2019 | 300 |
| 2020 | 254 |
| 2021 | 263 |
| 2022 | 235 |
| 2023 | 235 |
| 2024 | 254 |
| 2025 | 271 |
| 2026 | 174 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Movantik (Naloxegol Oxalate)
2024 spending
$153M
Beneficiaries
80,688
336,315 claims
Per beneficiary
$1,900
$13.50 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $12,413,099 |
| 2021 | $93,535,593 |
| 2022 | $121,381,425 |
| 2023 | $140,596,853 |
| 2024 | $153,330,440 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
Sponsor: Averitas
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.